Immunic
IMUX
58 hedge funds and large institutions have $28.3M invested in Immunic in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 9 closing their positions.
1,064% more call options, than puts
Call options by funds: $256K | Put options by funds: $22K
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0.06% less ownership
Funds ownership: 4.33% → 4.26% (-0.06%)
2% less funds holding
Funds holding: 59 → 58 (-1)
25% less capital invested
Capital invested by funds: $37.6M → $28.3M (-$9.38M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.21M |
| 2 |
Millennium Management
New York
|
+$2.12M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$1.47M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$495K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$365K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.39M |
| 2 |
Morgan Stanley
New York
|
-$741K |
| 3 |
Renaissance Technologies
New York
|
-$345K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$197K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$175K |
IMUX Hedge Fund Activity: Q4 2025 in Review
58 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2025, worth a combined $28.3M — down 25% from $37.6M a quarter earlier.
Fund positioning in IMUX was balanced in Q4 2025: 9 funds opened new positions, 9 closed out, 17 added to existing stakes and 9 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.21M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $1.39M sold.
- 58 institutional investors held Immunic (IMUX) as of Q4 2025, down from 59 in Q3 2025.
- Funds reported $28.3M of Immunic stock for Q4 2025, down 25% quarter-over-quarter.
- 9 funds opened new Immunic positions in Q4 2025 and 9 closed out, a net change of 0 holders.
- The largest Immunic buyer in Q4 2025 was Nantahala Capital Management, an estimated $3.21M added.
- The largest Immunic seller in Q4 2025 was Soleus Capital Management, an estimated $1.39M sold.
Based on aggregated 13F filings for Q4 2025.